Esperion Therapeutics,Inc. (NASDAQ:ESPR) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial Condition.
On May4, 2017, Esperion Therapeutics,Inc. issued a press release
announcing its financial results for the three months ended
March31, 2017 (the Press Release). A copy of the Press Release is
furnished herewith as Exhibit99.1.
The information set forth under Item 2.02 and in Exhibit99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934 or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, except as expressly set
forth by specific reference in such filing.
Item9.01 Financial Statements and Exhibits.
(d)Exhibits
|
ExhibitNo. |
|
Description |
|
99.1 |
Press Release dated May4, 2017. |
About Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid. Esperion Therapeutics, Inc. (NASDAQ:ESPR) Recent Trading Information
Esperion Therapeutics, Inc. (NASDAQ:ESPR) closed its last trading session down -0.87 at 36.94 with 502,553 shares trading hands.
